Literature DB >> 24140369

The DOPPS practice monitor for U.S. dialysis care: update on trends in anemia management 2 years into the bundle.

Douglas S Fuller1, Ronald L Pisoni, Brian A Bieber, Friedrich K Port, Bruce M Robinson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24140369     DOI： 10.1053/j.ajkd.2013.09.006

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN： 0272-6386            Impact factor:   8.860


× No keyword cloud information.
  22 in total

Review 1.  Considerations and challenges in defining optimal iron utilization in hemodialysis.

Authors:  David M Charytan; Amy Barton Pai; Christopher T Chan; Daniel W Coyne; Adriana M Hung; Csaba P Kovesdy; Steven Fishbane
Journal:  J Am Soc Nephrol       Date:  2014-12-26       Impact factor: 10.121

2.  Facility Practice Variation to Help Understand the Effects of Public Policy: Insights from the Dialysis Outcomes and Practice Patterns Study (DOPPS).

Authors:  Douglas S Fuller; Bruce M Robinson
Journal:  Clin J Am Soc Nephrol       Date:  2016-11-10       Impact factor: 8.237

3.  Safety of Intravenous Iron in Hemodialysis: Longer-term Comparisons of Iron Sucrose Versus Sodium Ferric Gluconate Complex.

Authors:  Wolfgang C Winkelmayer; Benjamin A Goldstein; Aya A Mitani; Victoria Y Ding; Medha Airy; Sreedhar Mandayam; Tara I Chang; M Alan Brookhart; Steven Fishbane
Journal:  Am J Kidney Dis       Date:  2017-01-04       Impact factor: 8.860

4.  Trends in Anemia Management in Hemodialysis Patients with Cancer.

Authors:  Anne M Butler; Abhijit V Kshirsagar; Andrew F Olshan; Matthew E Nielsen; Stephanie B Wheeler; M Alan Brookhart
Journal:  Am J Nephrol       Date:  2015-10-07       Impact factor: 3.754

Review 5.  Safety of intravenous iron in hemodialysis patients.

Authors:  Xiaojuan Li; Abhijit V Kshirsagar; M Alan Brookhart
Journal:  Hemodial Int       Date:  2017-04-03       Impact factor: 1.812

6.  A nationwide prospective cohort study of patients with advanced chronic kidney disease in Japan: The Reach-J CKD cohort study.

Authors:  Junichi Hoshino; Kei Nagai; Hirayasu Kai; Chie Saito; Yukiko Ito; Koichi Asahi; Masahide Kondo; Kunitoshi Iseki; Chiho Iseki; Hirokazu Okada; Naoki Kashihara; Ichiei Narita; Takashi Wada; Christian Combe; Ronald L Pisoni; Bruce M Robinson; Kunihiro Yamagata
Journal:  Clin Exp Nephrol       Date:  2017-07-24       Impact factor: 2.801

7.  The Phosphate Binder Ferric Citrate and Mineral Metabolism and Inflammatory Markers in Maintenance Dialysis Patients: Results From Prespecified Analyses of a Randomized Clinical Trial.

Authors:  Peter N Van Buren; Julia B Lewis; Jamie P Dwyer; Tom Greene; John Middleton; Mohammed Sika; Kausik Umanath; Josephine D Abraham; Shahabul S Arfeen; Isai G Bowline; Gil Chernin; Stephen Z Fadem; Simin Goral; Mark Koury; Marvin V Sinsakul; Daniel E Weiner
Journal:  Am J Kidney Dis       Date:  2015-05-07       Impact factor: 8.860

8.  Medicare Bundled Payment Policy on Anemia Care, Major Adverse Cardiovascular Events, and Mortality among Adults Undergoing Hemodialysis.

Authors:  Haesuk Park; Raj Desai; Xinyue Liu; Steven M Smith; Juan Hincapie-Castillo; Linda Henry; Amie Goodin; Saraswathi Gopal; Carl J Pepine; Raj Mohandas
Journal:  Clin J Am Soc Nephrol       Date:  2022-05-19       Impact factor: 10.614

9.  Understanding the Recent Increase in Ferritin Levels in United States Dialysis Patients: Potential Impact of Changes in Intravenous Iron and Erythropoiesis-Stimulating Agent Dosing.

Authors:  Angelo Karaboyas; Jarcy Zee; Hal Morgenstern; Jacqueline G Nolen; Raymond Hakim; Kamyar Kalantar-Zadeh; Philip Zager; Ronald L Pisoni; Friedrich K Port; Bruce M Robinson
Journal:  Clin J Am Soc Nephrol       Date:  2015-08-18       Impact factor: 8.237

10.  Efficiency of Original versus Generic Intravenous Iron Formulations in Patients on Haemodialysis.

Authors:  Maria Luisa Agüera; Alejandro Martin-Malo; Maria Antonia Alvarez-Lara; Victoria Eugenia Garcia-Montemayor; Petra Canton; Sagrario Soriano; Pedro Aljama
Journal:  PLoS One       Date:  2015-08-31       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.